諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄

美通社頭條

2025/09/24

、美通社消息：近日，《新英格蘭醫學雜誌》(The New England Journal of Medicine)發表了來自3期試驗OASIS 4的結果。此項試驗評估了在研的每日一次口服司美格魯肽片25 mg(Wegovy片劑)的有效性和安全性，標誌着諾和諾德在推進肥胖症治療方面達成一項重要的里程碑。在此項為期64周的試驗中，口服司美格魯肽片25mg聯合生活方式干預，在307名肥胖或超重且伴有至少...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569747572"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569747572\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569747572?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-24 08:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2569747572","market":"us","top_or_hot":-1,"title":"諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄","media":"美通社頭條","content":"<div>\n<p>、美通社消息：近日，《新英格蘭醫學雜誌》(The New England Journal of Medicine)發表了來自3期試驗OASIS 4的結果。此項試驗評估了在研的每日一次口服司美格魯肽片25 mg(Wegovy片劑)的有效性和安全性，標誌着諾和諾德在推進肥胖症治療方面達成一項重要的里程碑。在此項為期64周的試驗中，口服司美格魯肽片25mg聯合生活方式干預，在307名肥胖或超重且伴有至少...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">美通社頭條</strong><span class=\"h-time small\">2025-09-24 08:02</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>、美通社消息：近日，《新英格蘭醫學雜誌》(The New England Journal of Medicine)發表了來自3期試驗OASIS 4的結果。此項試驗評估了在研的每日一次口服司美格魯肽片25 mg(Wegovy片劑)的有效性和安全性，標誌着諾和諾德在推進肥胖症治療方面達成一項重要的里程碑。在此項為期64周的試驗中，口服司美格魯肽片25mg聯合生活方式干預，在307名肥胖或超重且伴有至少...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b\">美通社頭條</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"諾和諾德","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b","article_id":"2569747572","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569747572","pubTimestamp":1758672124,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"在此項為期64周的試驗中，口服司美格魯肽片25mg聯合生活方式干預，在307名肥胖或超重且伴有至少一種體重相關合併症但無糖尿病的成人患者中與安慰劑進行了對比。在不考慮患者依從性的情況下評估療效時，口服司美格魯肽片25 mg組患者仍然實現了13.6%的平均體重降幅，而安慰劑組這一數字則為2.2%。這些發現與此前進行的Wegovy注射液各項試驗結果一致。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"NVO":"诺和诺德","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4532":"文艺复兴科技持仓","BK4590":"PTP","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","BK4588":"碎股","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念"},"translate_title":"Novo Nordisk's efficacy data of the world's first oral GLP-1 weight loss drug breaks records","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"GLP":1.5},"content_text":"、美通社消息：近日，《新英格蘭醫學雜誌》(The New England Journal of Medicine)發表了來自3期試驗OASIS 4的結果。此項試驗評估了在研的每日一次口服司美格魯肽片25 mg(Wegovy片劑)的有效性和安全性，標誌着諾和諾德在推進肥胖症治療方面達成一項重要的里程碑。在此項為期64周的試驗中，口服司美格魯肽片25mg聯合生活方式干預，在307名肥胖或超重且伴有至少一種體重相關合併症但無糖尿病的成人患者中與安慰劑進行了對比。結果顯示，在64周時，在所有患者依從治療的情況下，口服司美格魯肽片25 mg組患者實現了16.6%的平均體重降幅，而安慰劑組這一數字則為2.7%；口服司美格魯肽片25 mg組患者中有1/3以上(34.4%)實現了20%及以上的體重降幅，安慰劑組這一比例為2.9%。這些數字與此前進行的Wegovy注射液各項試驗結果相當。在不考慮患者依從性的情況下評估療效時，口服司美格魯肽片25 mg組患者仍然實現了13.6%的平均體重降幅，而安慰劑組這一數字則為2.2%。口服司美格魯肽片25 mg組患者中有接近1/3(29.7%)實現了20%及以上的體重降幅，安慰劑組這一比例為3.3%。此外，研究還發現，相較於安慰劑，口服司美格魯肽片25 mg改善了心血管風險因素以及日常進行更多體力活動的能力。這些發現與此前進行的Wegovy注射液各項試驗結果一致。聯繫美通社+86-10-5953 9500info@prnasia.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}